ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.20
-0.01%
US Dollar vs AUD
1.50343
0.45%
Bitcoin
66,350.63
1.70%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) News

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNA
DateTimeSourceHeadlineSymbolCompany
17/05/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
17/05/202408:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202423:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
15/05/202423:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
15/05/202423:00PR Newswire (US)Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsNASDAQ:RNAAvidity Biosciences Inc
10/05/202406:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
10/05/202406:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
10/05/202406:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
10/05/202406:05PR Newswire (US)Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
09/05/202406:05PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
08/05/202420:00PR Newswire (US)Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1NASDAQ:RNAAvidity Biosciences Inc
08/05/202411:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
23/04/202406:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
28/03/202400:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
22/03/202407:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
09/03/202408:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
06/03/202408:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
04/03/202423:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
04/03/202423:00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialNASDAQ:RNAAvidity Biosciences Inc
02/03/202408:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
01/03/202408:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
01/03/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
01/03/202404:00PR Newswire (US)Avidity Biosciences Honors Rare Disease Day®NASDAQ:RNAAvidity Biosciences Inc
29/02/202423:00PR Newswire (US)Avidity Biosciences Announces Oversubscribed $400 Million Private PlacementNASDAQ:RNAAvidity Biosciences Inc
29/02/202409:32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
29/02/202408:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RNAAvidity Biosciences Inc
29/02/202408:05PR Newswire (US)Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
28/02/202401:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
22/02/202408:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
21/02/202401:00PR Newswire (US)Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 SkippingNASDAQ:RNAAvidity Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:RNA

Your Recent History

EU
DSY
Dassault Systemes
EU
D317T
D317T
BIT
UB516N
Unicredit Bank
LSE
56BS
LATK
BRIKETH
BRIKCOIN
BIT
WABC27
Abc
EU
BE0001724757
Region Wallonne RWALLO3....
XE
MWOE
Amundi ETF ICAV
LSE
NDH
BIT
F16283
Vontobel Financial Produ...
BMF
ICFU18
COIN
TTUMBTC
EU
4721T
4721T
AQSE
OMIP.GB
One Media IP
COIN
INXPUST
InsightProtocol
BIT
Q00515
Leonteq Securities
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved